<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908985</url>
  </required_header>
  <id_info>
    <org_study_id>EYEMUST-FLUO</org_study_id>
    <nct_id>NCT01908985</nct_id>
  </id_info>
  <brief_title>Ocular Fluorophotometry for Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).</brief_title>
  <official_title>Ocular Fluorophotometry to Assess the Aqueous Humor Production for Patients With Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeTechCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyeTechCare</source>
  <brief_summary>
    <textblock>
      Monocentric prospective study conducted in two phases evaluating the secretion and&#xD;
      elimination of aqueous humor by fluorophotometry in patients with glaucoma treated with&#xD;
      cyclo-coagulation with ultrasound.&#xD;
&#xD;
      Population selected:&#xD;
&#xD;
      - Patients with refractory open angle glaucoma despite previous treatments currently&#xD;
      validated for glaucoma.&#xD;
&#xD;
      The purpose of our study is:&#xD;
&#xD;
      - To evaluate the mechanism of action of glaucoma treatment by cyclo-coagulation with high&#xD;
      intensity focused ultrasound in studying the secretion and elimination of aqueous humor by&#xD;
      fluorophotometry.&#xD;
&#xD;
      Planning:&#xD;
&#xD;
        -  First phase: 2 patients (feasibility study) If reduction of at least 10% of the flow of&#xD;
           aqueous humor production at one month in the first two patients in the feasibility&#xD;
           study, further in second phase.&#xD;
&#xD;
        -  Second phase: 6 patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main outcome criteria:&#xD;
&#xD;
      Reduction of aqueous humor flow at 6 months compared with the pretreatment of aqueous humor&#xD;
      flow.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Refractory Open Angle Glaucoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high intensity focused ultrasound for cyclodestruction in the eye</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  refractory primary open-angle glaucoma (POAG)&#xD;
&#xD;
          -  IOP&gt; 21 mm Hg and &lt;32 mm Hg with an optimal treatment.&#xD;
&#xD;
          -  Lack of history of cyclo-destruction of the ciliary body (laser diode, cold ...)&#xD;
&#xD;
          -  Lack of intraocular surgery or laser therapy in the eye seen in the three months&#xD;
             preceding the date of HIFU treatment.&#xD;
&#xD;
          -  Male or female age (s) of at least 18 and able to give informed consent&#xD;
&#xD;
          -  Patient who signed the informed consent form&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of glaucoma by placing a drainage implant (valves, pipes ...)&#xD;
&#xD;
          -  previous refractive procedures preventing accurate measurement of intraocular pressure&#xD;
             (PRK, LASIK)&#xD;
&#xD;
          -  General treatment which may alter IOP began in the month before the HIFU procedure&#xD;
&#xD;
          -  Patient monophthalmus&#xD;
&#xD;
          -  thyroid orbitopathy&#xD;
&#xD;
          -  History of ocular or retrobulbar tumor&#xD;
&#xD;
          -  Cyclodialysis&#xD;
&#xD;
          -  choroidal hematoma or uprising choroidal&#xD;
&#xD;
          -  Anatomy of the eyeball inadequate treatment or medical device (eye too small or too&#xD;
             large)&#xD;
&#xD;
          -  Pregnancy, breastfeeding, lack of contraceptive use among women at risk of having a&#xD;
             child&#xD;
&#xD;
          -  Participation in another clinical investigation of a medical or surgical treatment can&#xD;
             affect the intraocular pressure in the three months preceding the HIFU&#xD;
&#xD;
          -  Patient minor or major protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>high intensity focused ultrasound</keyword>
  <keyword>aqueous humor</keyword>
  <keyword>fluorophotometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

